Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

NCT06160609 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to lack of efficacy.

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: Belantamab Mafodotin
DRUG: GSK3174998

Sponsor

GlaxoSmithKline